Logo image of CELU

CELULARITY INC-A (CELU) Stock Fundamental Analysis

NASDAQ:CELU - Nasdaq - US1511902041 - Common Stock - Currency: USD

2.49  +0.39 (+18.57%)

After market: 2.5 +0.01 (+0.4%)

Fundamental Rating

1

Taking everything into account, CELU scores 1 out of 10 in our fundamental rating. CELU was compared to 561 industry peers in the Biotechnology industry. CELU has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CELU is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CELU has reported negative net income.
CELU had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CELU reported negative net income in multiple years.
CELU had a negative operating cash flow in each of the past 5 years.
CELU Yearly Net Income VS EBIT VS OCF VS FCFCELU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

The Return On Assets of CELU (-27.21%) is better than 69.70% of its industry peers.
CELU has a worse Return On Equity (-202.85%) than 69.52% of its industry peers.
Industry RankSector Rank
ROA -27.21%
ROE -202.85%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CELU Yearly ROA, ROE, ROICCELU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -20 -40 -60 -80 -100

1.3 Margins

CELU has a better Gross Margin (64.20%) than 79.50% of its industry peers.
CELU does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CELU Yearly Profit, Operating, Gross MarginsCELU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

CELU does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for CELU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CELU Yearly Shares OutstandingCELU Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 5M 10M
CELU Yearly Total Debt VS Total AssetsCELU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -10.60, we must say that CELU is in the distress zone and has some risk of bankruptcy.
CELU has a worse Altman-Z score (-10.60) than 76.11% of its industry peers.
A Debt/Equity ratio of 2.47 is on the high side and indicates that CELU has dependencies on debt financing.
With a Debt to Equity ratio value of 2.47, CELU is not doing good in the industry: 82.35% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.47
Debt/FCF N/A
Altman-Z -10.6
ROIC/WACCN/A
WACC9.89%
CELU Yearly LT Debt VS Equity VS FCFCELU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

CELU has a Current Ratio of 0.19. This is a bad value and indicates that CELU is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.19, CELU is doing worse than 96.61% of the companies in the same industry.
A Quick Ratio of 0.14 indicates that CELU may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.14, CELU is doing worse than 96.97% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.14
CELU Yearly Current Assets VS Current LiabilitesCELU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.54% over the past year.
The Revenue has grown by 225.94% in the past year. This is a very strong growth!
EPS 1Y (TTM)85.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.29%
Revenue 1Y (TTM)225.94%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%145.54%

3.2 Future

Based on estimates for the next years, CELU will show a decrease in Earnings Per Share. The EPS will decrease by -9.54% on average per year.
Based on estimates for the next years, CELU will show a very strong growth in Revenue. The Revenue will grow by 48.52% on average per year.
EPS Next Y-62.86%
EPS Next 2Y-9.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-68.68%
Revenue Next 2Y2.27%
Revenue Next 3Y3.99%
Revenue Next 5Y48.52%

3.3 Evolution

CELU Yearly Revenue VS EstimatesCELU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
CELU Yearly EPS VS EstimatesCELU Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CELU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELU Price Earnings VS Forward Price EarningsCELU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELU Per share dataCELU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A cheap valuation may be justified as CELU's earnings are expected to decrease with -9.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.54%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CELU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELULARITY INC-A

NASDAQ:CELU (5/22/2025, 8:00:00 PM)

After market: 2.5 +0.01 (+0.4%)

2.49

+0.39 (+18.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-19 2025-05-19
Earnings (Next)07-28 2025-07-28/amc
Inst Owners14.98%
Inst Owner Change6.99%
Ins Owners16.73%
Ins Owner Change0.3%
Market Cap55.98M
Analysts82.86
Price TargetN/A
Short Float %16.85%
Short Ratio17.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.16
P/FCF N/A
P/OCF N/A
P/B 3.24
P/tB 181.15
EV/EBITDA N/A
EPS(TTM)-1.52
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS2.14
BVpS0.77
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.21%
ROE -202.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.2%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 2.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.21%
Cap/Sales 1.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.14
Altman-Z -10.6
F-Score5
WACC9.89%
ROIC/WACCN/A
Cap/Depr(3y)56.42%
Cap/Depr(5y)N/A
Cap/Sales(3y)25.33%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.29%
EPS Next Y-62.86%
EPS Next 2Y-9.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)225.94%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%145.54%
Revenue Next Year-68.68%
Revenue Next 2Y2.27%
Revenue Next 3Y3.99%
Revenue Next 5Y48.52%
EBIT growth 1Y-212.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-141.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y91.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y91.21%
OCF growth 3YN/A
OCF growth 5YN/A